Taiwan Bio-Manufacturing Corporation (TBMC) today announced its collaboration with Medigen Vaccine Biologics Corp. (MVC, 6547.TWO), Taiwan’s leading vaccine company. Through this collaboration, TBMC will leverage its integrated CRDMO platform to support antigen process development for MVC’s “Second-Generation Multivalent Enterovirus Vaccine,” accelerating development timelines and further strengthening the self-reliant development and manufacturing capabilities of Taiwan’s vaccine industry.

BIO Asia–Taiwan 2026 takes place from July 16–19, 2026. During the event, TBMC is showcasing its capabilities in advanced therapy process development and GMP manufacturing, while sharing the company’s latest developments, drawing industry attention and media coverage.

Taiwan Bio-Manufacturing Corporation (TBMC) today held the opening ceremony of its GMP facility in Zhubei, located at the Hsinchu Biomedical Science Park. The facility is Taiwan’s first GMP site equipped with mRNA manufacturing capabilities, marking a significant milestone for the country’s biopharmaceutical industry as it enters a new era of advanced biomanufacturing. The opening also signals a new phase in TBMC’s CRDMO service development.

Taiwan Bio-Manufacturing Corporation (TBMC), a CDMO focused on advanced therapeutics, is currently building a GMP-compliant manufacturing facility in the Hsinchu Biomedical Science Park.

TBMC CEO David Chang was interviewed by The Chemical Daily on the company’s future growth strategy.

◆ 經濟日報  CRDMO國家隊 新廠將量產 年產1,300萬劑mRNA疫苗

◆ 環球生技  TBMC營業額成長1.8倍 年底GMP廠完工估1300萬劑疫苗

◆ 自由時報  台灣生物醫藥製造TBMC旗下GMP工廠 明年Q2投產

◆ 中央社  TBMC啟動GMP廠建置明年量產 疫苗年產量達1300萬劑

◆ 鉅亨網  〈亞洲生技大展〉TBMC上半年營收、接單皆已超越2024全年 竹北GMP厰明年Q1啟用

◆ MoneyDJ新聞  TBMC今年接單/營收跳升，GMP廠明年Q1啟用

◆ 新唐人電視  CDMO需求旺台廠急擴廠 關稅在即強化韌性應對

◆ 生技女王投資勝經  CDMO群聚效益現，TBMC、台康生技、永昕均有亮點

Taiwan Bio-Manufacturing Corporation (TBMC) held a groundbreaking ceremony today (26th) at Hsinchu Biomedical Science Park, officially initiating the construction of Taiwan’s first GMP manufacturing base for mRNA nucleic acid medicines and vaccines. This marks a significant milestone in TBMC’s expansion into the global CRDMO (Contract Research, Development, and Manufacturing Organization) market for biopharmaceuticals.

At the opening of the ceremony, Chairman Patrick Yang stated:
“The COVID-19 pandemic has highlighted the crucial role of mRNA technology in preventing and treating emerging infectious diseases. TBMC’s mission is to bring world-class manufacturing capabilities and technologies for cutting-edge medicines to Taiwan, safeguarding public health and national security. The launch of our GMP facility not only demonstrates our production capacity and quality control capabilities, but also represents a key milestone in TBMC’s journey toward becoming a world-class pharmaceutical CRDMO.”

The GMP facility is designed by a renowned U.S. team and built in compliance with international GMP standards. Featuring a highly flexible and modular design, it can accommodate complex advanced drug processes and future scale-up requirements. The initial phase will focus on mRNA nucleic acid medicines and vaccines as well as cell therapy production lines.

For mRNA nucleic acid medicines, the facility will cover the entire upstream process from plasmid linearization to lipid nanoparticle-encapsulated mRNA production, supporting emerging vaccines and rare disease therapies. The initial annual production capacity is expected to reach 13 million doses of mRNA vaccines, strengthening Taiwan’s domestic vaccine production capability and national pandemic resilience.

For cell therapy, the facility will provide manufacturing services for mesenchymal stem cells, CAR-T, and other immune cells, supporting preclinical studies, clinical trials, and commercial-scale production.

The GMP facility is scheduled for completion by the end of 2025 and is expected to commence operations in the first half of 2026. The QC laboratory and quality systems, which are already under construction, will be completed later this year to support subsequent GMP validation and process verification. TBMC also plans to expand production to gene therapies and complex biologics, broadening its overall service portfolio.

Prior to the new facility, TBMC had already established process and analytical services laboratories in Taipei and Hsinchu Biomedical Science Park in 2024, providing services for domestic and international clients in nucleic acid, cell, gene therapy, and biologics. Upon completion of the GMP facility, TBMC will offer a fully integrated, end-to-end platform covering upstream process development, analytical services, and downstream manufacturing.

Future Outlook
TBMC will relentlessly build a world-class global CRDMO platform, accelerating the transformation of innovative therapies from the laboratory to the commercial market, elevating Taiwan’s biopharmaceutical manufacturing capabilities, and forging stronger links with the global biomedical industry.